Clinical Trial Update: Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates on a combination of olaparib and temozolomide in recurrent small cell lung cancer after prior chemotherapy failure (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Olaparib (Olaparib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Zofia Piotrowska | Conditions: Small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN